Cynthia Aranow

List of Publications by Year
in descending order

88 papers	8,131 citations	136885 32 h-index	82499 72 g-index
88 all docs	88 docs citations	88 times ranked	9069 citing authors

#	Article	IF	Citations
1	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis and Rheumatism, 2012, 64, 2677-2686.	6.7	3,838
2	Vitamin D and the Immune System. Journal of Investigative Medicine, 2011, 59, 881-886.	0.7	827
3	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Annals of the Rheumatic Diseases, 2015, 74, 1706-1713.	0.5	391
4	The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology, 2016, 55, 252-262.	0.9	370
5	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Annals of the Rheumatic Diseases, 2017, 76, 554-561.	0.5	268
6	Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. Annals of the Rheumatic Diseases, 2012, 71, 1502-1509.	0.5	143
7	Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis. Arthritis and Rheumatology, 2021, 73, 121-131.	2.9	117
8	A Multicenter, Randomized, Doubleâ€Blind, Placeboâ€Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis. Arthritis and Rheumatology, 2016, 68, 2174-2183.	2.9	105
9	Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis and Rheumatology, 2015, 67, 1837-1847.	2.9	98
10	2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Science and Medicine, 2021, 8, e000538.	1.1	97
11	Headache in Systemic Lupus Erythematosus: Results From a Prospective, International Inception Cohort Study. Arthritis and Rheumatism, 2013, 65, 2887-2897.	6.7	84
12	Transcutaneous auricular vagus nerve stimulation reduces pain and fatigue in patients with systemic lupus erythematosus: a randomised, double-blind, sham-controlled pilot trial. Annals of the Rheumatic Diseases, 2021, 80, 203-208.	0.5	82
13	Randomized, Doubleâ€Blind, Placeboâ€Controlled Trial of the Effect of Vitamin D₃ on the Interferon Signature in Patients With Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2015, 67, 1848-1857.	2.9	73
14	Selective Impairment of Spatial Cognition Caused by Autoantibodies to the N-Methyl-d-Aspartate Receptor. EBioMedicine, 2015, 2, 755-764.	2.7	71
15	Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Annals of the Rheumatic Diseases, 2015, 74, 1530-1536.	0.5	70
16	Antinuclear Antibodyâ€“Negative Systemic Lupus Erythematosus in an International Inception Cohort. Arthritis Care and Research, 2019, 71, 893-902.	1.5	70
17	Checkpoints for Autoreactive B Cells in the Peripheral Blood of Lupus Patients Assessed by Flow Cytometry. Arthritis and Rheumatology, 2016, 68, 2210-2220.	2.9	65
18	Longâ€Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2018, 70, 868-877.	2.9	63

#	Article	IF	Citations
19	Lupus community panel proposals for optimising clinical trials: 2018. Lupus Science and Medicine, 2018, 5, e000258.	1.1	62
20	Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis Care and Research, 2018, 70, 1478-1487.	1.5	55
21	Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis and Rheumatology, 2019, 71, 281-289.	2.9	55
22	Metabolic and microstructural alterations in the SLE brain correlate with cognitive impairment. JCI Insight, 2019, 4, .	2.3	52
23	Safety, pharmacokinetics and pharmacodynamics of AMG 811, an anti-interferon-Î³ monoclonal antibody, in SLE subjects without or with lupus nephritis. Lupus Science and Medicine, 2017, 4, e000226.	1.1	49
24	Inhibition of IRF5 hyperactivation protects from lupus onset and severity. Journal of Clinical Investigation, 2020, 130, 6700-6717.	3.9	48
25	Understanding the Antibody Repertoire in Neuropsychiatric Systemic Lupus Erythematosus and Neuromyelitis Optica Spectrum Disorder. Arthritis and Rheumatology, 2018, 70, 277-286.	2.9	45
26	Glutamate Receptor Biology and its Clinical Significance in Neuropsychiatric Systemic Lupus Erythematosus. Rheumatic Disease Clinics of North America, 2010, 36, 187-201.	0.8	42
27	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Annals of the Rheumatic Diseases, 2022, 81, 370-378.	0.5	42
28	A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. Arthritis and Rheumatology, 2016, 68, 1932-1944.	2.9	40
29	Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. Annals of the Rheumatic Diseases, 2020, 79, 356-362.	0.5	40
30	Differences in Regional Brain Activation Patterns Assessed by Functional Magnetic Resonance Imaging in Patients with Systemic Lupus Erythematosus Stratified by Disease Duration. Molecular Medicine, 2011, 17, 1349-1356.	1.9	39
31	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis and Rheumatology, 2020, 72, 67-77.	2.9	39
32	Molecular signatures in systemic lupus erythematosus: distinction between disease flare and infection. Lupus Science and Medicine, 2016, 3, e000159.	1.1	37
33	Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. Rheumatology, 2018, 57, 677-687.	0.9	37
34	Loss of an IgG plasma cell checkpoint in patients with lupus. Journal of Allergy and Clinical Immunology, 2019, 143, 1586-1597.	1.5	36
35	Brain metabolism and autoantibody titres predict functional impairment in systemic lupus erythematosus. Lupus Science and Medicine, 2015, 2, e000074-e000074.	1.1	34
36	Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study. Rheumatology, 2020, 59, 2930-2938.	0.9	33

#	Article	IF	Citations
37	Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines. Arthritis Research and Therapy, 2018, 20, 133.	1.6	30
38	Alterations in Blood-Brain Barrier Permeability in Patients with Systemic Lupus Erythematosus. American Journal of Neuroradiology, 2019, 40, 470-477.	1.2	28
39	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. Journal of Autoimmunity, 2020, 106, 102340.	3.0	27
40	Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. Arthritis and Rheumatology, 2020, 72, 658-666.	2.9	26
41	Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2019, 71, 1297-1307.	2.9	25
42	Patterns of ANA+ B cells for SLE patient stratification. JCI Insight, 2019, 4, .	2.3	25
43	Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. Arthritis Care and Research, 2020, 72, 1800-1808.	1.5	23
44	Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria. Arthritis Care and Research, 2021, 73, 1231-1235.	1.5	22
45	Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. Arthritis Care and Research, 2018, 70, 1294-1302.	1.5	21
46	Laboratory investigation results influence Physicianâ€™s Global Assessment (PGA) of disease activity in SLE. Annals of the Rheumatic Diseases, 2020, 79, 787-792.	0.5	20
47	Remission in SLE: closing in on the target. Annals of the Rheumatic Diseases, 2015, 74, 2103-2106.	0.5	19
48	Blood-Borne RNA Correlates with Disease Activity and IFN-Stimulated Gene Expression in Systemic Lupus Erythematosus. Journal of Immunology, 2016, 197, 2854-2863.	0.4	18
49	Dynamic Contrast-Enhanced MRI Reveals Unique Blood-Brain Barrier Permeability Characteristics in the Hippocampus in the Normal Brain. American Journal of Neuroradiology, 2019, 40, 408-411.	1.2	18
50	Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. Arthritis and Rheumatology, 2020, 72, 1734-1740.	2.9	17
51	Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study. Lancet Rheumatology, The, 2022, 4, e441-e449.	2.2	17
52	A pilot study to determine the optimal timing of the Physician Global Assessment (PGA) in patients with systemic lupus erythematosus. Immunologic Research, 2015, 63, 167-169.	1.3	15
53	Comparison of the Lupus Foundation of America-Rapid Evaluation of Activity in Lupus to More Complex Disease Activity Instruments As Evaluated by Clinical Investigators or Real-World Clinicians. Arthritis Care and Research, 2018, 70, 1058-1063.	1.5	13
54	Discrepant Perception of Lupus Disease Activity. Journal of Clinical Rheumatology, 2020, 26, S165-S169.	0.5	13

#	Article	IF	Citations
55	Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications. Arthritis Care and Research, 2021, 73, 1789-1795.	1.5	13
56	Serologic features of cohorts with variable genetic risk for systemic lupus erythematosus. Molecular Medicine, 2018, 24, 24.	1.9	12
57	Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. Annals of the Rheumatic Diseases, 2019, 78, 1010-1012.	0.5	12
58	Assessing cognitive impairment in SLE: examining relationships between resting glucose metabolism and anti-NMDAR antibodies with navigational performance. Lupus Science and Medicine, 2019, 6, e000327.	1.1	11
59	Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus. Rheumatology, 2021, 60, 5379-5389.	0.9	11
60	Quinolinic acid, a kynurenine/tryptophan pathway metabolite, associates with impaired cognitive test performance in systemic lupus erythematosus. Lupus Science and Medicine, 2021, 8, e000559.	1.1	10
61	Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICCâ€FI). Arthritis Care and Research, 2020, , .	1.5	9
62	Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Annals of the Rheumatic Diseases, 2022, 81, 1143-1150.	0.5	9
63	Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus. Arthritis Care and Research, 2022, 74, 1822-1828.	1.5	9
64	Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. Rheumatology, 2019, 58, 1259-1267.	0.9	8
65	Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort. Arthritis and Rheumatology, 2021, 73, 2293-2302.	2.9	7
66	Evaluating the Construct of Damage in Systemic Lupus Erythematosus. Arthritis Care and Research, 2023, 75, 998-1006.	1.5	7
67	Reliability of Visual Analog Scale and Numeric Rating Scale for the Assessment of Disease Activity in Systemic Lupus Erythematosus. Journal of Clinical Rheumatology, 2020, 26, S170-S173.	0.5	5
68	Effect of vitamin D on serum markers of bone turnover in SLE in a randomised controlled trial. Lupus Science and Medicine, 2019, 6, e000352.	1.1	3
69	A double-blind, placebo-controlled, phase II, randomized study of lovastatin therapy in the treatment of mildly active rheumatoid arthritis. Rheumatology, 2020, 59, 1505-1513.	0.9	3
70	Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset. Lupus, 2021, 30, 096120332110142.	0.8	3
71	Determination of the minimal clinically important difference (MCID) of the physician global assessment (PGA) in SLE. Annals of the Rheumatic Diseases, 2022, 81, 1336-1337.	0.5	2
72	Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study. Arthritis Research and Therapy, 2017, 19, 287.	1.6	1

#	Article	IF	Citations
73	AI-18â€...The effect of belimumab on B cell selection in human SLE. , 2018, , .		1
74	Reply:. American Journal of Neuroradiology, 2019, 40, E42-E43.	1.2	1
75	TD-05â€...Dynamic contrast enhanced MRI (DCE-MRI) demonstrates hippocampus permeability in SLE. , 2018, , .		0
76	CS-07â€...Economic evaluation of damage accrual in an international SLE inception cohort. , 2018, , .		0
77	CT-03â€...Phase 2 trial of induction therapy with anti-CD20 (rituximab) followed by maintenance therapy with anti-BAFF (belimumab) in patients with active lupus nephritis. , 2018, , .		0
78	178â€...Phase 2 trial of induction therapy with anti-CD20 (Rituximab) followed by maintenance therapy with anti-BAFF (Belimumab) in patients with active lupus nephritis. , 2019, , .		0
79	209â€...Attainment of low disease activity and remission with atacicept in patients with systemic lupus erythematosus and high disease activity in the phase IIb ADDRESS II study and its long-term extension. , 2019, , .		0
80	Reply:. American Journal of Neuroradiology, 2019, 40, E67-E68.	1.2	0
81	Response to: â€˜Physician global assessment in systemic lupus erythematosus: can we rely on its reliability?â€™ by Chessa et al. Annals of the Rheumatic Diseases, 2020, , annrheumdis-2020-217692.	0.5	0
82	The brain in SLE. , 2021, , 231-255.		0
83	Response to: â€˜Phsician's global assessment is often useful in SLE, but not always: the case of clinical remissionâ€™ by Zenet al. Annals of the Rheumatic Diseases, 2020, , annrheumdis-2020-217687.	0.5	0
84	1105â€...Telemedicine in rheumatology: a survey of patient and provider satisfaction with virtual care. , 2021, , .		0
85	1124â€...Economic evaluation of neuropsychiatric (NP) lupus in an international inception cohort using a multistate model approach. , 2021, , .		0
86	1107â€...Economic evaluation of hydroxychloroquine use in an international inception cohort. , 2021, , .		0
87	801â€...Factors associated with SLE flares after HCQ taper, discontinuation or maintenance in the SLICC inception cohort: lower education linked with higher flare risk. , 2021, , .		0
88	1704â€...Identifying clusters of longitudinal autoantibody profiles associated with systemic lupus erythematosus disease outcomes. , 2021, , .		0